Study of Heat Shock Protein 47 as a New Marker for Blood Clot Risk in Adults with Venous Thromboembolism, Heart Attack, or Stroke Compared to Healthy Volunteers

What this Trial Is About

Researchers are studying whether the novel biomarker Heat Shock Protein 47 HSP47 can serve as a prognostic marker for vascular disease in people who have experienced acute venous thromboembolism VTE, acute myocardial infarction AMI, or ischemic stroke, compared to healthy volunteers. The study aims to determine if platelet levels of HSP47 are higher in these patients at diagnosis and whether these levels remain elevated at 3 and 12 months after the event. It also explores the relationship between HSP47 levels, platelet function, and fibrinolytic capacity in patients with acute thrombotic events. This observational study includes four groups patients with acute VTE diagnosed by ultrasonography or pulmonary embolism diagnosed by CT angiography patients with ST segment elevation myocardial infarction confirmed by coronary angiography patients with stroke confirmed by MRI and atrial fibrillation and healthy participants with no known diseases or medications. Patients provide blood samples at diagnosis and again at 3 and 12 months, while healthy volunteers provide a single blood sample. Participants will undergo blood sampling and monitoring for platelet levels of HSP47 and related platelet function over the study period. The primary outcome is the comparison of platelet HSP47 levels between patients and healthy controls at diagnosis and follow-up. Secondary outcomes include changes in HSP47 over time and its associations with platelet function and fibrinolytic capacity. The study is sponsored by the University of Aarhus and will continue until August 2027.

Heat Shock Protein 47 in Thrombosis